Randomized Prospective Comparison of Everolimus-Eluting vs. Sirolimus-Eluting Stents in Patients Undergoing Percutaneous Coronary Intervention-3-Year Clinical Outcomes of the EXCELLENT Randomized Trial -
- Authors
- Park, Kyung Woo; Rhee, Tae-Min; Kang, Hyun-Jae; Koo, Bon-Kwon; Gwon, Hyeon-Cheol; Yoon, Jung-Han; Lim, Do-Sun; Chae, In-Ho; Han, Kyoo-Rok; Ahn, Taehoon; Jeong, Myung-Ho; Jeon, Dong-Woon; Jang, Yang-Soo; Kim, Hyo-Soo
- Issue Date
- Jun-2018
- Publisher
- JAPANESE CIRCULATION SOC
- Keywords
- Everolimus; Percutaneous coronary intervention; Sirolimus; Stent
- Citation
- CIRCULATION JOURNAL, v.82, no.6, pp.1566 - +
- Indexed
- SCIE
SCOPUS
- Journal Title
- CIRCULATION JOURNAL
- Volume
- 82
- Number
- 6
- Start Page
- 1566
- End Page
- +
- URI
- https://scholar.korea.ac.kr/handle/2021.sw.korea/75453
- DOI
- 10.1253/circj.CJ-17-0677
- ISSN
- 1346-9843
- Abstract
- Background: Everolimus-eluting stents (EES) have equivalent short-term angiographic and clinical outcomes to sirolimus-eluting stents (SES), but EES may be superior to SES with regard to long-term clinical safety. We report the 3-year clinical outcomes of EES and SES from the prospective EXCELLENT Randomized Trial (NCT00698607). Methods and Results: We randomly assigned 1,443 patients undergoing percutaneous coronary intervention 3: 1 to receive EES and SES, respectively. We investigated endpoints including target lesion failure (TLF) and individual clinical outcomes including stent thrombosis (ST) at 3 years. For EES and SES, the TLF rate was 4.82% and 4.12% (risk ratio [RR], 1.16, 95% CI: 0.65-2.06, P=0.62), respectively. Results were similar in other efficacy endpoints including target lesion revascularization. For safety endpoints, rate of all-cause death was significantly lower for EES (1.67%) than SES (3.57%; RR, 0.46; 95% CI: 0.23-0.94, P=0.03), while the incidence of cardiac death or myocardial infarction was numerically lower in EES. On 1-year landmark analysis, rates of all-cause death and major adverse cardiovascular events were significantly lower for EES than SES. Definite or probable ST was numerically 3-fold higher for SES (1.37%) compared with EES (0.46%). Conclusions: EES and SES had similar efficacy with regard to 3-year outcomes in the EXCELLENT trial, while delayed safety events all trended to favor EES.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - Graduate School > Department of Biomedical Sciences > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholar.korea.ac.kr/handle/2021.sw.korea/75453)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.